🏢 官网IRSRPTDoubao · 实盘不做把握 9/10不做原因:无增量信息
北京时间·🕒 发布 20:30:00(美东 08:30)·⟳ 抓取 20:37:53回填·⚡ 决策 10-22 20:39:50·5.3 天前
Sarepta Therapeutics 宣布将于2026年11月5日盘后发布Q3财报并召开电话会，纯日程预告无业绩增量
本稿是例行财报发布日期与电话会日程通知（date-holder/save-the-date），不含收入、利润、EPS、指引、订单或管线数据，无任何相对预期的增量事实，无法建立方向或交易edge；待2026-11-05盘后实际Q3财报发布后再据surprise独立研判。
📄 原文SRPT↗ 原文
Sarepta Therapeutics to Announce Third Quarter 2026 Financial Results
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 22, 2026-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision g…
不做 Sarepta Therapeutics, Inc.（SRPT.US）
纯财报发布日期/电话会日程预告（save-the-date），无收入、EPS、指引、订单或管线增量，方向中性、无预期差与可交易edge；待2026-11-05盘后实际Q3财报发布后再独立研判，不在日程稿上提前建仓。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Sarepta仅预告Q3财报将于11月5日盘后发布，全文无业绩或指引数字，属中性程序性日程公告，无预期差与可交易edge，本次不做。
主要风险
- 实际财报在11月5日盘后才发布，当前提前建仓等于无信息支撑的方向性押注；Sarepta作为罕见病基因治疗公司，财报前后受Elevidys销售与临床/监管消息影响波动可能较大。
先例如何影响了这次决策
对本次决策的影响:确认本次直接AVOID，不在日程稿上提前建仓；等待11月5日实际财报再研判。
方向:无需外部价格先例：本稿不含任何业绩/指引增量，事件类型本身（财报日期预告）不产生方向，历史同类date-holder公告的处理结论一致为不做。
涨幅量级:无增量事实，不设止盈幅度；不应以未来财报波动率倒推当前交易。
形态:近72小时已处理库中TRIP、KRT、SERV、DSP、DKNG、ARQT、DGII、VECO、MBUU、CRAI等十余家公司的同类Q3财报日程稿均判定为纯date-holder、不做，处理模式高度一致。
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 1,931 ms
{"result": "search_processed_events:agent query=`sarepta therapeutics third quarter 2026 financial results date | srpt q3 2026 earnings conference call november 5`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 72.0/72 小时、26124 条本臂决策(完整)，返回 10 条候选。\n• 10-20 20:08 UTC(北京 10-21 04:08) [bm25:51%] 不做 TRIP.US (wire) — Tripadv
原文全文
展开原文 · 1,870 字
CAMBRIDGE, Mass.
--(BUSINESS WIRE)--Oct. 22, 2026--
Sarepta Therapeutics, Inc.
(NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2026 financial results after the Nasdaq Global Market closes on
Thursday, Nov. 5, 2026
. Subsequently, at
4:30 p.m. ET
, the Company will host a conference call to discuss these results.
The event will be webcast live under the investor relations section of Sarepta's website at
https://investorrelations.sarepta.com/events-presentations
and following the event a replay will be archived there for one year. Interested parties participating by phone will need to register using
this online form
. After registering for dial-in details, all phone participants will receive an auto-generated e-mail containing a link to the dial-in number along with a personal PIN number to use to access the event by phone.
About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold a leadership position in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at
www.sarepta.com
. We encourage investors and potential investors to consult our website regularly for important information about us.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20261022410590/en/
Investor Contacts:
Ian Estepan, 617-274-4052,
iestepan@sarepta.com
Ryan Wong, 617-800-4112,
rwong@sarepta.com
Tam Thornton, 617-803-3825,
tthornton@sarepta.com
Media Contact:
Tracy Sorrentino, 617-301-8566,
tsorrentino@sarepta.com
Source: Sarepta Therapeutics, Inc.
--(BUSINESS WIRE)--Oct. 22, 2026--
Sarepta Therapeutics, Inc.
(NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2026 financial results after the Nasdaq Global Market closes on
Thursday, Nov. 5, 2026
. Subsequently, at
4:30 p.m. ET
, the Company will host a conference call to discuss these results.
The event will be webcast live under the investor relations section of Sarepta's website at
https://investorrelations.sarepta.com/events-presentations
and following the event a replay will be archived there for one year. Interested parties participating by phone will need to register using
this online form
. After registering for dial-in details, all phone participants will receive an auto-generated e-mail containing a link to the dial-in number along with a personal PIN number to use to access the event by phone.
About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold a leadership position in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at
www.sarepta.com
. We encourage investors and potential investors to consult our website regularly for important information about us.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20261022410590/en/
Investor Contacts:
Ian Estepan, 617-274-4052,
iestepan@sarepta.com
Ryan Wong, 617-800-4112,
rwong@sarepta.com
Tam Thornton, 617-803-3825,
tthornton@sarepta.com
Media Contact:
Tracy Sorrentino, 617-301-8566,
tsorrentino@sarepta.com
Source: Sarepta Therapeutics, Inc.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
3a7ec99308· 2026-10-22 20:39 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前